|1.||Kaunitz, A M: 2 articles (12/2000 - 05/2000)|
|2.||Mitchell, Jennifer: 1 article (07/2015)|
|3.||Gasperino, James: 1 article (07/2015)|
|4.||Simsovits, Debra: 1 article (07/2015)|
|5.||Abraham, Mary: 1 article (07/2015)|
|6.||Gucev, Z: 1 article (12/2012)|
|7.||Tasic, V: 1 article (12/2012)|
|8.||Polenakovic, M: 1 article (12/2012)|
|9.||Fisher, Alan C: 1 article (07/2003)|
|10.||Burkman, Ronald: 1 article (07/2003)|
07/01/1984 - "Clinical studies in the US, Canada, and France have shown that Ortho-Novum 7/7/7 is effective and safe, that it reduces midcycle breakthrough bleeding sometimes seen in patients on biphasic therapy, that side effects occur infrequently, and that metabolic impact is low. "
05/01/2000 - "For each of the months of the study, the incidence of breakthrough bleeding/spotting was lower in the Cyclessa group than the Ortho-Novum 7/7/7 group (breakthrough bleeding, p = 0.006; breakthrough spotting, p = 0.001). "
12/01/1986 - " Later studies showed that intermenstrual bleeding in the early cycles of Triella use later diminished."
09/01/1990 - "Loestrin subjects had a rate of occurrence (31% of cycles) for intermenstrual bleeding (IMB) comparable to the rates for subjects on the phasic preparations (36%, 37% and 37%, respectively). "
05/01/2000 - "Despite a lower ethinyl estradiol dose (25 microg/day vs. 35 microg/day), the Cyclessa group had significantly improved cycle control in comparison to the Ortho-Novum 7/7/7 group for presence of a withdrawal bleed (p = 0.001), lack of early withdrawal bleed (p = 0.01), and breakthrough bleeding/spotting (p = 0.001). "
12/01/2002 - "The responsiveness of the Acne-QoL was demonstrated through its ability to detect both small (baseline to mid-study) and moderate (baseline to study end) treatment advantages for Estrostep patients. "
12/01/2002 - "The Acne-QoL was utilized in two randomized, double-blind, placebo-controlled studies of the efficacy of Estrostep (norethindrone acetate/ethinyl estradiol) in the treatment of facial acne; a total of 296 Estrostep and 295 placebo patients were evaluated. "
01/01/2003 - "Score changes on this instrument have been used to report statistically significant treatment advantages for a low-dose oral contraceptive (Estrostep, containing norethisterone (norethindrone) acetate (NA) 1mg and ethinylestradiol (EE) [20, 30, 35 mg] as compared with placebo in women with moderate acne vulgaris. "
02/01/2001 - "Although true androgenic activity can be determined only by assessing endpoints such as acne, hirsutism, and lipids in large controlled trials, the observed changes in circulating SHBG and free testosterone concentrations indicate that Estrostep has little, if any, intrinsic androgenic activity."
09/01/1990 - "Loestrin, Ortho 10/11 and Ortho 7/7/7 subjects were more likely to report amenorrhea (p less than 0.001) and less likely to report leg cramps (p less than 0.01) compared to those on Triphasil. "
09/01/1992 - "Eleven women with hyperprolactinemic amenorrhea were treated with a combined estrogen/progestogen preparation (Loestrin 30) for 3 months as hormone replacement therapy because of estrogen deficiency, with a view to protection against osteoporosis. "
05/01/1990 - " The percentage of women experiencing breakthrough bleeding in their 1st year of use was 18.4% among Ortho-Novum 7/7/7 users, 17.8% among Ortho-Novum 1/35 users, and 11.2% among Triphasil users; the percentages of women reporting amenorrhea were 3.0%, 12.8%, and 0.0%, respectively. "
05/01/1990 - "Differences in breakthrough bleeding, amenorrhea, and patient compliance among users of monophasic (Ortho-Novum 1/35) and triphasic (Triphasil and Ortho-Novum 7/7/7) oral contraceptives (OCs) were investigated in a prospective study at a Michigan family planning clinic. "
05/01/2000 - "The contraceptive efficacy and safety of Cyclessa is comparable to Ortho-Novum 7/7/7. Cyclessa provides significantly improved cycle control with no weight gain."
09/01/1979 - "The numbers discontinuing treatment were about the same in the three groups, the main reasons being intermenstrual spotting in those on Netagen 423, amenorrhoea and weight gain in those on Netagen 403 and nausea and weight gain in those on Netasyn. "
|1.||Ethinyl Estradiol (Estinyl)
|2.||norethindrone acetate (Norlutate)
|4.||Norinyl (Ortho Novum)
|7.||Ethinyl Estradiol-Norgestrel Combination (Ovral)
|8.||ethynylestradiol mixture with norethindrone (Zoran)
|1.||Hormone Replacement Therapy (Therapy, Hormone Replacement)